celecoxib has been researched along with paclitaxel in 28 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (21.43) | 29.6817 |
| 2010's | 20 (71.43) | 24.3611 |
| 2020's | 2 (7.14) | 2.80 |
| Authors | Studies |
|---|---|
| Bilter, GK; Dias, J; Huang, Z; Keon, BH; Lamerdin, J; MacDonald, ML; Michnick, SW; Minami, T; Owens, S; Shang, Z; Westwick, JK; Yu, H | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Benfenati, E; Raska, I; Toropov, AA; Toropova, AP | 1 |
| Benet, LZ; Brouwer, KL; Chu, X; Dahlin, A; Evers, R; Fischer, V; Giacomini, KM; Hillgren, KM; Hoffmaster, KA; Huang, SM; Ishikawa, T; Keppler, D; Kim, RB; Lee, CA; Niemi, M; Polli, JW; Sugiyama, Y; Swaan, PW; Tweedie, DJ; Ware, JA; Wright, SH; Yee, SW; Zamek-Gliszczynski, MJ; Zhang, L | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| He, WJ; Li, DX; Liu, YH; Liu, YQ; Wang, JF; Yang, SH; Zhang, XX; Zhou, XJ | 1 |
| He, WJ; Liu, YH; Wang, JF; Zhang, XX; Zhao, BQ; Zhou, XJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Altorki, NK; Dannenberg, AJ; Ferrara, CA; Flieder, DB; Keresztes, RS; Korst, RJ; Libby, DM; Pasmantier, MW; Port, JL; Subbaramaiah, K; Yankelevitz, DF | 1 |
| Bubley, GJ; He, X; Jayaram, DR; Merchan, JR; Sukhatme, VP; Supko, JG | 1 |
| Chae, IH; Cho, YS; Choi, DJ; Chung, JW; Chung, WY; Hahn, JY; Kang, HJ; Kim, HS; Kim, YS; Koo, BK; Kwon, DA; Lee, HY; Oh, BH; Park, JS; Park, KW; Park, YB; Yang, HM; Youn, TJ | 1 |
| Carbone, DP; Choy, H; Csiki, I; Johnson, DH; Lu, B; Moretti, L; Morrow, JD; Mutter, R; Sandler, AB; Shyr, Y; Ye, F | 1 |
| Atkins, MB; Bhatt, RS; Heymach, JV; McDermott, D; Merchan, J; Parker, R; Seery, V; Sukhatme, VP; Wu, HK; Zhang, L | 1 |
| Chae, IH; Cho, YS; Choi, DJ; Chung, JW; Kang, HJ; Kim, HS; Koo, BK; Lee, HY; Oh, BH; Park, JS; Park, KW; Park, YB; Yang, HM; Youn, TJ | 1 |
| Chen, YJ; Liu, Q; Liu, XJ; Wang, J | 1 |
| Cai, JH; Li, W; Tang, YX; Wan, L; Zhang, J | 1 |
| Bell, R; Khasraw, M | 1 |
| Cai, J; Li, W; Liu, M; Tang, Y; Zhai, L; Zhang, J | 1 |
| Dhanda, DS; Kompella, UB; Mirvish, SS; Tyagi, P | 1 |
| Huang, H; Liu, Y; Ren, J; Zheng, X; Zou, Q | 1 |
| Kim, HS; Lee, BM; Lim, JS; Park, Y; Yoon, S | 1 |
| Hu, Y; Jiang, T; Jin, K; Liu, X; Luo, Z; Pang, Z; Shen, S; Tuo, Y; Wang, L; Zhang, B | 1 |
| Choi, HG; Hong, SS; Kim, JH; Kim, JK; Kim, JO; Kim, SY; Lim, SJ; Thapa, RK | 1 |
| Emami, J; Kazemi, M; Rezazadeh, M; Ziaei, E | 1 |
| Hedayat, M; Jafari, R; Khezri, MR; Majidi Zolbanin, N; Malekinejad, H | 1 |
3 review(s) available for celecoxib and paclitaxel
| Article | Year |
|---|---|
Membrane transporters in drug development.
Topics: Animals; Computer Simulation; Decision Trees; Drug Approval; Drug Discovery; Drug Evaluation, Preclinical; Drug Interactions; Humans; Membrane Transport Proteins; Mice; Mice, Knockout; Prescription Drugs | 2010 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Primary systemic therapy in HER2-amplified breast cancer: a clinical review.
Topics: Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Breast Neoplasms; Carboplatin; Celecoxib; Chemotherapy, Adjuvant; Clinical Trials as Topic; Docetaxel; Female; Humans; Lapatinib; Mastectomy, Segmental; Paclitaxel; Pyrazoles; Quinazolines; Randomized Controlled Trials as Topic; Receptor, ErbB-2; Sulfonamides; Taxoids; Trastuzumab | 2012 |
6 trial(s) available for celecoxib and paclitaxel
| Article | Year |
|---|---|
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, enhances the response to preoperative paclitaxel and carboplatin in early-stage non-small-cell lung cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Chemotherapy, Adjuvant; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Synergism; Female; Follow-Up Studies; Humans; Lung Neoplasms; Male; Maximum Tolerated Dose; Middle Aged; Paclitaxel; Pneumonectomy; Preoperative Care; Pyrazoles; Sulfonamides; Survival Analysis; Treatment Outcome | 2003 |
Increased endothelial uptake of paclitaxel as a potential mechanism for its antiangiogenic effects: potentiation by Cox-2 inhibition.
Topics: Angiogenesis Inhibitors; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Collagen; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Drug Combinations; Endothelial Cells; Enzyme-Linked Immunosorbent Assay; Humans; In Vitro Techniques; Isoenzymes; Laminin; Lung; Male; Melanoma; Membrane Proteins; Neovascularization, Pathologic; Paclitaxel; Prostaglandin-Endoperoxide Synthases; Prostatic Neoplasms; Proteoglycans; Pyrazoles; Skin; Skin Neoplasms; Sulfonamides; Time Factors; Tumor Cells, Cultured; Umbilical Veins | 2005 |
Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study.
Topics: Aged; Angioplasty, Balloon, Coronary; Antineoplastic Agents, Phytogenic; Celecoxib; Coronary Restenosis; Cyclooxygenase Inhibitors; Disease-Free Survival; Drug Therapy, Combination; Female; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Paclitaxel; Prospective Studies; Pyrazoles; Stents; Sulfonamides | 2007 |
A phase II study of celecoxib in combination with paclitaxel, carboplatin, and radiotherapy for patients with inoperable stage IIIA/B non-small cell lung cancer.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Carcinoma, Non-Small-Cell Lung; Celecoxib; Combined Modality Therapy; Cyclooxygenase 2 Inhibitors; Female; Humans; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Paclitaxel; Prostaglandins; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2009 |
A phase 2 pilot trial of low-dose, continuous infusion, or "metronomic" paclitaxel and oral celecoxib in patients with metastatic melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Cytokines; Drug Administration Schedule; Female; Humans; Male; Melanoma; Middle Aged; Neoplasm Metastasis; Paclitaxel; Pilot Projects; Pyrazoles; Skin Neoplasms; Sulfonamides | 2010 |
Long-term outcome of adjunctive celecoxib treatment after paclitaxel-eluting stent implantation for the complex coronary lesions: two-year clinical follow-up of COREA-TAXUS trial.
Topics: Aged; Celecoxib; Chemotherapy, Adjuvant; Constriction, Pathologic; Coronary Vessels; Cyclooxygenase 2 Inhibitors; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Male; Middle Aged; Paclitaxel; Prosthesis Implantation; Pyrazoles; Sulfonamides; Treatment Outcome | 2010 |
19 other study(ies) available for celecoxib and paclitaxel
| Article | Year |
|---|---|
Identifying off-target effects and hidden phenotypes of drugs in human cells.
Topics: Bacterial Proteins; Cell Line; Cell Proliferation; Cluster Analysis; Drug Design; Drug Evaluation, Preclinical; Genetics; Humans; Luminescent Proteins; Molecular Structure; Phenotype; Recombinant Fusion Proteins; Signal Transduction; Structure-Activity Relationship | 2006 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
QSPR modeling of octanol/water partition coefficient of antineoplastic agents by balance of correlations.
Topics: Antineoplastic Agents; Models, Chemical; Octanols; Quantitative Structure-Activity Relationship; Water | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Five new phorbol esters with cytotoxic and selective anti-inflammatory activities from Croton tiglium.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Cell Line; Cell Proliferation; Croton; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase Inhibitors; Dose-Response Relationship, Drug; Humans; Molecular Structure; Phorbol Esters; Structure-Activity Relationship | 2015 |
Dicarabrol, a new dimeric sesquiterpene from Carpesium abrotanoides L.
Topics: Antineoplastic Agents, Phytogenic; Asteraceae; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Conformation; Sesquiterpenes; Structure-Activity Relationship | 2015 |
[Effect of combination of taxol and celecoxib on reversing multidrug resistance human breast cancer cells (MCF-7/ Taxol) and explore its underlying mechanism].
Topics: Antineoplastic Agents, Phytogenic; Breast Neoplasms; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Paclitaxel; Pyrazoles; Sulfonamides | 2011 |
Effects of cyclooxygenase inhibitors in combination with taxol on expression of cyclin D1 and Ki-67 in a xenograft model of ovarian carcinoma.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Proliferation; Cyclin D1; Cyclooxygenase Inhibitors; Female; Humans; Immunoenzyme Techniques; Ki-67 Antigen; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Sulfonamides; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2012 |
Antitumor properties of taxol in combination with cyclooxygenase-1 and cyclooxygenase-2 selective inhibitors on ovarian tumor growth in vivo.
Topics: Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Celecoxib; Cell Proliferation; Cyclooxygenase 1; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Female; Humans; Immunoenzyme Techniques; In Situ Nick-End Labeling; Mice; Mice, Nude; Ovarian Neoplasms; Paclitaxel; Pyrazoles; Sulfonamides; Tumor Cells, Cultured | 2012 |
Supercritical fluid technology based large porous celecoxib-PLGA microparticles do not induce pulmonary fibrosis and sustain drug delivery and efficacy for several weeks following a single dose.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzo(a)pyrene; Bronchoalveolar Lavage Fluid; Carboplatin; Celecoxib; Cell Count; Collagen; Delayed-Action Preparations; Female; L-Lactate Dehydrogenase; Lactic Acid; Lung Neoplasms; Mice; Paclitaxel; Particle Size; Polyglycolic Acid; Polylactic Acid-Polyglycolic Acid Copolymer; Porosity; Pulmonary Fibrosis; Pyrazoles; Sulfonamides; Vascular Endothelial Growth Factor A | 2013 |
An Atomic Force Microscope Study Revealed Two Mechanisms in the Effect of Anticancer Drugs on Rate-Dependent Young's Modulus of Human Prostate Cancer Cells.
Topics: Amino Acids; Celecoxib; Cell Line, Tumor; Cytoskeleton; Disulfiram; Elastic Modulus; Fluorescent Antibody Technique; Heterocyclic Compounds, 3-Ring; Humans; Male; Microscopy, Atomic Force; Models, Theoretical; Paclitaxel; Prostatic Neoplasms | 2015 |
Co-treatment with Celecoxib or NS398 Strongly Sensitizes Resistant Cancer Cells to Antimitotic Drugs Independent of P-gp Inhibition.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Antimitotic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Celecoxib; Cell Line, Tumor; Cyclooxygenase 2 Inhibitors; Drug Resistance, Neoplasm; Drug Synergism; Humans; Nitrobenzenes; Paclitaxel; Sulfonamides; Vinblastine | 2016 |
Celecoxib normalizes the tumor microenvironment and enhances small nanotherapeutics delivery to A549 tumors in nude mice.
Topics: A549 Cells; Adenocarcinoma, Bronchiolo-Alveolar; Animals; Antineoplastic Agents, Phytogenic; Celecoxib; Cyclooxygenase 2; Cyclooxygenase 2 Inhibitors; Drug Administration Schedule; Drug Delivery Systems; Drug Synergism; Drug Therapy, Combination; Gene Expression; Humans; Lung Neoplasms; Male; Mice; Mice, Nude; Micelles; Nanoparticles; Neovascularization, Pathologic; Paclitaxel; Polyesters; Polyethylene Glycols; Tumor Burden; Tumor Microenvironment; Xenograft Model Antitumor Assays | 2017 |
Role of zein incorporation on hydrophobic drug-loading capacity and colloidal stability of phospholipid nanoparticles.
Topics: Celecoxib; Colloids; Curcumin; Docetaxel; Drug Carriers; Hydrophobic and Hydrophilic Interactions; Nanoparticles; Paclitaxel; Particle Size; Phospholipids; Surface Properties; Zein | 2018 |
Simultaneous Determination of Docetaxel and Celecoxib in Porous Microparticles and Rat Plasma by Liquid-Liquid Extraction and HPLC with UV Detection: in vitro and in vivo Validation and Application.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Chromatography, High Pressure Liquid; Docetaxel; Drug Monitoring; Limit of Detection; Liquid-Liquid Extraction; Male; Microspheres; Paclitaxel; Porosity; Rats; Rats, Wistar; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2020 |
Concomitant effects of paclitaxel and celecoxib on genes involved in apoptosis of triple-negative metastatic breast cancer cells.
Topics: Apoptosis; bcl-2-Associated X Protein; Breast Neoplasms; Caspase 3; Celecoxib; Cell Line, Tumor; Female; Humans; Paclitaxel; Proto-Oncogene Proteins c-bcl-2; Triple Negative Breast Neoplasms | 2023 |